HIGHLIGHTS
- who: Roman Reindl-Schwaighofer from the Institute for Clinical and Experimental Thammasat University, Thailand have published the Article: Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial, in the Journal: (JOURNAL)
- what: In the current analysis of the randomized controlled trial (RCT), including follow-up data on antibody levels until month 3, the authors aimed to assess changes in antibody over time (month 1 to month 3) following homologous vs. heterologous 3rd vaccination. The aim of the present trial, however . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.